Biocon Biologics grants Sandoz exclusive rights to market biosimilar adalimumab in Japan
Adalimumab BS for subcutaneous injection is indicated for immune-related diseases such as rheumatoid arthritis, psoriasis vulgaris, ankylosing spondylitis, Crohn's disease, and ulcerative colitis.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: Ankylosing Spondylitis | Arthritis | Biotechnology | Crohn's Disease | Grants | Humira | Inflammatory Bowel Disease | Japan Health | Pharmaceuticals | Psoriasis | Rheumatoid Arthritis | Rheumatology | Ulcerative Colitis